Page 94

Mayo_2017

artículo de revisión Nuevas tecnologías en el tratamiento de la diabetes - P. Apablaza et al Complicated by Problematic Hypoglycemia. Diabetes Care 2015; 38 (6): 1016-29. 31. Barnard K, Skinner T. Qualitative study into quality of life issues surrounding insulin pump use in type 1 diabetes. Pract Diab Int 2007; 24 (3): 143-8. 32. De Vries L, Grushka Y, Lebenthal Y, Shalitin S, Phillip M. Factors associated with increased risk of insulin pump discontinuation in pediatric patients with type 1 diabetes. Pediatr Diabetes 2011; 12 (5): 506-12. 33. Scheen A, Castillo M, Jandrain B, Krzentowski G, Henrivaux 640 P, Luyckx A, et al. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusión. Diabetes Care 1984; 7 (4): 338-42. 34. Guerci B, Meyer L, Sallé A, Charrié A, Dousset B, Ziegler O, et al. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients. J Clin Endocrinol Metab 1999; 84 (8): 2673-8. 35. Realsen J, Goettle H, Chase P. Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol The 2012; 14 (12): 1149-54. 36. Mecklenburg R, Benson E, Benson J, Fredlund P, Guinn T, Metz R, et al. Acute complications associated with insulin infusion pump therapy. Report of experience with 161 patients. JAMA 1984; 21; 252 (23): 3265-9. 37. Pickup J, Yemane N, Brackenridge A, Pender S. Nonmetabolic Complications of Continuous Subcutaneous Insulin Infusion: A Patient Survey. Diabetes Technol Ther 2014; 16 (3): 145-9. 38. Wheeler B, Donaghue K, Heels K, Ambler G. Family Perceptions of Insulin Pump Adverse Events in Children and Adolescents. Diabetes Technol Ther 2014; 16 (4): 204-7. 39. Wheeler B, Heels K, Donaghue K, Reith D, Ambler G. Insulin pump-associated adverse events in children and adolescents-a prospective study. Diabetes Technol Ther 2014; 16 (9): 558-62. 40. St Charles M, Lynch P, Graham C, Minshall M. A cost-effectiveness analysis of continuous subcutaneous insulin injection versus multiple daily injections in type 1 diabetes patients: a third-party US payer perspective. Value Health 2009; 12 (5): 674-86. 41. Roze S, Valentine W, Zakrzewska K, Palmer A. Health- economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK. Diabet Med 2005; 22 (9): 1239-45. 42. Cohen N, Minshall M, Sharon-Nash L, Zakrzewska K, Valentine W, Palmer A. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin: economic comparison in adult and adolescent type 1 diabetes mellitus in Australia. Pharmacoeconomics 2007; 25 (10): 881-97. 43. Cummins E, Royle P, Snaith A, Greene A, Robertson L, McIntyre L, et al. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. Health Technol Assess 2010; 14 (11): iii-iv, xi-xvi, 1-181. 44. Norgaard K, Sohlberg A, Goodall G. Cost-effectiveness of continuous subcutaneous insulin infusion therapy for type 1 diabetes. Ugeskr Laeger 2010; 172 (27): 2020-5. 45. Tamborlane W, Beck R, Bode B, Buckingham B, Chase H, Clemons R, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359 (14): 1464-76. 46. Bergenstal R, Tamborlane W, Ahmann A, Buse J, Dailey G, Davis S, et al. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 2010; 363 (4): 311-20. 47. Battelino T, Conget I, Olsen B, Schütz-Fuhrmann I, Hommel E, Hoogma R. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 2012; 55 (12): 3155-62. 48. Roze S, Saunders R, Brandt A, De Portu S, Papo N, Jendle J. Health-economic analysis of real-time continuous glucose monitoring in people with Type 1 diabetes. Diabet Med 2015; 32 (5): 618-26. 49. Huang E, O’Grady M, Basu A, Winn A, John P, Lee J. The cost-effectiveness of continuous glucose monitoring in type 1 diabetes. Diabetes Care 2010; 33 (6): 1269-74. 50. Ly T, Brnabic A, Eggleston A, Kolivos A, McBride M, Schrover R, et al. A cost-effectiveness analysis of sensor augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes. Value Health 2014; 17 (5): 561-9. 51. Roze S, Smith-Palmer J, Valentine W, Cook M, Jethwa M, De Portu S, et al. Long-term health economic benefits of sensor-augmented pump therapy vscontinuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. J Med Econ 2016; 19 (3): 236-42. Rev Med Chile 2017; 145: 630-640


Mayo_2017
To see the actual publication please follow the link above